Recent safety concerns regarding JAK inhibitors, particularly after a safety study in a clinical trial of tofacitinib versus tumour necrosis factor (TNF) inhibitor in subjects with rheumatoid arthritis, also referred to as the ORAL Surveillance trial, have led regulatory agencies to issue restrictions and boxed warnings, highlighting the need for careful patient selection [12]. The gene discussed is TNF; the disease is rheumatoid arthritis.